Comparison of impact and cost-effectiveness of rotavirus supplementary and routine immunization in a complex humanitarian emergency, Somali case study

详细信息    查看全文

• 作者：Lisa M Gargano (1)
  Jacqueline E Tate (2)
  Umesh D Parashar (2)
  Saad B Omer (3)
  Susan T Cookson (1)
  
  1. Center for Global Health ; Centers for Disease Control and Prevention ; 4770 Buford Highway ; Atlanta ; GA ; 30341 ; USA
  2. National Center for Immunization and Respiratory Diseases ; Centers for Disease Control and Prevention ; Atlanta ; GA ; USA
  3. Rollins School of Public Health ; Emory University ; Atlanta ; GA ; USA
  
• 关键词：Rotavirus vaccine ; Humanitarian emergency ; Somalia ; Cost ; effectiveness ; Routine immunization
• 刊名：Conflict and Health
• 出版年：2015
• 出版时间：December 2015
• 年：2015
• 卷：9
• 期：1
• 全文大小：477 KB
• 参考文献：1. Inter-Agency Standing Committee. [http://www.humanitarianinfo.org/iasc/]
  2. A Year of Crises, Global Trends 2011. [http://www.unhcr.org/4fd6f87f9.html]
  3. Reducing Measles Mortality in Emergencies. [http://www.who.int/immunization_delivery/adc/measles/measles_emergencies.pdf]
  4. World Health Organization. Manual for the Health Care of Children in Humanitarian Emergencies. In: Book Manual for the Health Care of Children in Humanitarian Emergencies. 2008. (Editor ed.^eds.). City.
  5. Dennehy PH. Transmission of rotavirus and other enteric pathogens in the home. Pediatr Infect Dis J. 2000;19:S103鈥?. CrossRef
  6. Kotloff KL, Nataro JP, Blackwelder WC, Nasrin D, Farag TH, Panchalingam S, et al. Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case鈥揷ontrol study. Lancet. 2013;382:209鈥?2. CrossRef
  7. Parashar UD, Hummelman EG, Bresee JS, Miller MA, Glass RI. Global illness and deaths caused by rotavirus disease in children. Emerg Infect Dis. 2003;9:565鈥?2. CrossRef
  8. Tate JE, Burton AH, Boschi-Pinto C, Steele AD, Duque J, Parashar UD, et al. 2008 estimate of worldwide rotavirus-associated mortality in children younger than 5聽years before the introduction of universal rotavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12:136鈥?1. CrossRef
  9. Simpson E, Wittet S, Bonilla J, Gamazina K, Cooley L, Winkler JL. Use of formative research in developing a knowledge translation approach to rotavirus vaccine introduction in developing countries. BMC Public Health. 2007;7:281. CrossRef
  10. Glass RI, Bresee JS, Turcios R, Fischer TK, Parashar UD, Steele AD. Rotavirus vaccines: targeting the developing world. J Infect Dis. 2005;192 Suppl 1:S160鈥?. CrossRef
  11. Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, Abate H, Breuer T, Clemens SC, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med. 2006;354:11鈥?2. CrossRef
  12. Vesikari T, Matson DO, Dennehy P, Van Damme P, Santosham M, Rodriguez Z, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med. 2006;354:23鈥?3. CrossRef
  13. Age of administration of rotavirus vaccines. [http://www.who.int/vaccine_safety/committee/topics/rotavirus/rotarix_and_rotateq/7Aug_2009_age_administration/en/index.html]
  14. Country National Immunization Program (NIP) Introductions of Rotavirus Vaccine. [http://sites.path.org/rotavirusvaccine/files/2014/01/Country-Introduction-Table_EN_2014-01-14_edit.pdf]
  15. Giaquinto C, Dominiak-Felden G, Van Damme P, Myint TT, Maldonado YA, Spoulou V, et al. Summary of effectiveness and impact of rotavirus vaccination with the oral pentavalent rotavirus vaccine: a systematic review of the experience in industrialized countries. Hum Vaccin. 2011;7:734鈥?8. CrossRef
  16. World Health Organization. Rotavirus vaccines, WHO position paper - January 2013. Wkly Epidemiol Rec. 2013;5:49鈥?4.
  17. Menkhaus K. Governance without government in Somalia: spoilers, state building, and the politics of coping. Int Secur. 2006;31:74鈥?06. CrossRef
  18. Dagne T. Somalia: prospects for a lasting peace. Mediterr Q. 2009;20:95鈥?12. CrossRef
  19. World Development Indicators. [http://databank.worldbank.org/ddp/home.do]
  20. Vijayaraghavan M, Wallace A, Mirza IR, Kamadjeu R, Nandy R, Durry E, et. al. Economic Evaluation of a Child Health Days Strategy to Deliver Multiple Maternal and Child Health Interventions in Somalia. J Infect Dis. 2012;205 Suppl 1:S134-40.
  21. Somalia: WHO and UNICEF estimates of immunization coverage, 1997鈥?009. [http://www.childinfo.org/files/Somalia_1997-2009_updated.pdf]
  22. Somalia: WHO and UNICEF estimates of immunization coverage: 2013 revision. [http://www.childinfo.org/files/somalia_rev_13_FINAL.pdf]
  23. UNICEF sends in health experts to prevent cholera epidemic in Somalia. [http://www.unicef.org/infobycountry/somalia_59971.html]
  24. Centers for Disease Control and Prevention. Poliomyelitis outbreak in Somalia and Kenya, 2013. Releve epidemiologique hebdomadaire / Section d鈥檋ygiene du Secretariat de la Societe des Nations = Weekly epidemiological record / Health Section of the Secretariat of the League of Nations. 2013;88:349鈥?5.
  25. Kim SY, Sweet S, Slichter D, Goldie SJ. Health and economic impact of rotavirus vaccination in GAVI-eligible countries. BMC Public Health. 2010;10:253. CrossRef
  26. World Health Organization, SAGE: SAGE working group on vaccination in humanitarian emergencies. In Book SAGE working group on vaccination in humanitarian emergencies (Editor ed.^eds.). City: World Health Organization; 2012.
  27. Country hub: Somalia. [http://www.gavialliance.org/country/somalia/]
  28. Patel MM, Clark AD, Sanderson CF, Tate J, Parashar UD. Removing the age restrictions for rotavirus vaccination: a benefit-risk modeling analysis. PLoS Med. 2012;9:e1001330. CrossRef
  29. Cunliffe NA, Gondwe JS, Kirkwood CD, Graham SM, Nhlane NM, Thindwa BD, et al. Effect of concomitant HIV infection on presentation and outcome of rotavirus gastroenteritis in Malawian children. Lancet. 2001;358:550鈥?. CrossRef
  30. Multiple Indicator Cluster Survey (MICS) 3. [http://www.childinfo.org/mics3_surveys.html]
  31. Lamberti LM, Fischer Walker CL, Black RE. Systematic review of diarrhea duration and severity in children and adults in low- and middle-income countries. BMC Public Health. 2012;12:276. CrossRef
  32. Berry SA, Johns B, Shih C, Berry AA, Walker DG. The cost-effectiveness of rotavirus vaccination in Malawi. J Infect Dis. 2010;202(Suppl):S108鈥?5. CrossRef
  33. Tate JE, Kisakye A, Mugyenyi P, Kizza D, Odiit A, Braka F. Projected health benefits and costs of pneumococcal and rotavirus vaccination in Uganda. Vaccine. 2011;29:3329鈥?4. CrossRef
  34. Centers for Disease Control and Prevention. Nationwide measles vaccination campaign for children aged 6 months-12 years--Afghanistan, 2002. MMWR Morb Mortal Wkly Rep. 2003;52:363鈥?.
  35. Centers for Disease Control and Prevention. Emergency measles control activities--Darfur, Sudan, 2004. MMWR Morb Mortal Wkly Rep. 2004;53:897鈥?.
  36. Grais RF, Strebel P, Mala P, Watson J, Nandy R, Gayer M. Measles vaccination in humanitarian emergencies: a review of recent practice. Conflict Health. 2011;5:21. CrossRef
  37. United Nations High Commissoner for Refugees. Nutrition Surveys Dadaab Refugee Camps, August/September 2011. In: Book Nutrition Surveys Dadaab Refugee Camps, August/September. 2011. (Editor ed.^eds.). City.
  38. Global Immunization Data. [http://www.who.int/immunization_monitoring/Global_Immunization_Data.pdf]
  39. Abbott C, Tiede B, Armah G, Mahmoud A. Evaluation of cost-effectiveness of live oral pentavalent reassortant rotavirus vaccine introduction in Ghana. Vaccine. 2012;30:2582鈥?. CrossRef
  40. Introduction of rotavirus vaccine with support from the GAVI Alliance: information to assist the national decision-making and application process. [http://sites.path.org/rotavirusvaccine/files/2014/01/Country-Introduction-Table_EN_2014-01-14_edit.pdf]
  41. CHOsing Interventions that are Cost Effective (WHO-CHOICE). [http://www.who.int/choice/en/]
  42. Parashar UD, Gibson CJ, Bresee JS, Glass RI. Rotavirus and severe childhood diarrhea. Emerg Infect Dis. 2006;12:304鈥?. CrossRef
  43. Infant Mortality Rate. [http://www.cia.gov/library/publications/the-world-factbook/fields/2091.html]
  44. Mortality Country Fact Sheet 2006. [http://www.afro.who.int/en/tanzania/tanzania-publications/2690-mali-publications.html]
  45. GAVI Alliance secures lower price for rotavirus vaccine. [http://www.gavi.org/library/news/press-releases/2012/gavi-secures-lower-price-rotavirus-vaccine/]
  46. WHO vaccine-preventable diseases: monitoring system. 2013 global update. [http://apps.who.int/immunization_monitoring/globalsummary/estimates?c=SOM]
  47. Madhi SA, Cunliffe NA, Steele D, Witte D, Kirsten M, Louw C, et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. N Engl J Med. 2010;362:289鈥?8. CrossRef
  48. Salomon JA, Vos T, Hogan DR, Gagnon M, Naghavi M, Mokdad A, et al. Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet. 2012;380:2129鈥?3. CrossRef
  49. Salomon JA, Wang H, Freeman MK, Vos T, Flaxman AD, Lopez AD, et al. Healthy life expectancy for 187 countries, 1990鈥?010: a systematic analysis for the Global Burden Disease Study 2010. Lancet. 2012;380:2144鈥?2. CrossRef
  50. Rheingans RD, Heylen J, Giaquinto C. Economics of rotavirus gastroenteritis and vaccination in Europe: what makes sense? Pediatr Infect Dis J. 2006;25:S48鈥?5. CrossRef
  51. Centers for Disease Control and Prevention. Measles--Horn of Africa, 2010鈥?011. MMWR Morb Mortal Wkly Rep. 2012;61:678鈥?4.
  52. Sudfeld CR, Navar AM, Halsey NA. Effectiveness of measles vaccination and vitamin A treatment. Int J Epidemiol. 2010;39 Suppl 1:i48鈥?5. CrossRef
  53. Cost-effectiveness Thresholds. [http://www.who.int/choice/costs/CER_thresholds/en/index.html]
  54. UN Data. [http://data.un.org/]
  55. Rheingans RD, Antil L, Dreibelbis R, Podewils LJ, Bresee JS, Parashar UD. Economic costs of rotavirus gastroenteritis and cost-effectiveness of vaccination in developing countries. J Infect Dis. 2009;200 Suppl 1:S16鈥?7. CrossRef
  56. De la Hoz F, Alvis N, Narvaez J, Cediel N, Gamboa O, Velandia M. Potential epidemiological and economical impact of two rotavirus vaccines in Colombia. Vaccine. 2010;28:3856鈥?4. CrossRef
  57. Sinha A, Levine O, Knoll MD, Muhib F, Lieu TA. Cost-effectiveness of pneumococcal conjugate vaccination in the prevention of child mortality: an international economic analysis. Lancet. 2007;369:389鈥?6. CrossRef
  58. Serazin AC, Shackelton LA, Wilson C, Bhan MK. Improving the performance of enteric vaccines in the developing world. Nat Immunol. 2010;11:769鈥?3. CrossRef
  59. Assis AM, Barreto ML, Santos LM, Fiaccone R, da Silva Gomes GS. Growth faltering in childhood related to diarrhea: a longitudinal community based study. Eur J Clin Nutr. 2005;59:1317鈥?3. CrossRef
  60. Moodley K, Hardie K, Selgelid MJ, Waldman RJ, Strebel P, Rees H, et al. Ethical considerations for vaccination programmes in acute humanitarian emergencies. Bull World Health Organ. 2013;91:290鈥?. CrossRef
  61. Patel MM, Lopez-Collada VR, Bulhoes MM, De Oliveira LH, Bautista Marquez A, Flannery B, et al. Intussusception risk and health benefits of rotavirus vaccination in Mexico and Brazil. N Engl J Med. 2011;364:2283鈥?2. CrossRef
  62. Buttery JP, Danchin MH, Lee KJ, Carlin JB, McIntyre PB, Elliott EJ, et al. Intussusception following rotavirus vaccine administration: post-marketing surveillance in the National Immunization Program in Australia. Vaccine. 2011;29:3061鈥?. CrossRef
  63. Gillmann N. Interagency Coordination during Disaster: Strategic Choices for the Un, Ngos, and Other Humaniatarian Actors in the Field Nomos Publishers. Seattle, Washington: PATH; 2010. CrossRef
  
• 刊物主题：Medicine/Public Health, general; Emergency Medicine;
• 出版者：BioMed Central
• ISSN：1752-1505

文摘

Background A humanitarian emergency involves a complete breakdown of authority that often disrupts routine health care delivery, including immunization. Diarrheal diseases are a principal cause of morbidity and mortality among children during humanitarian emergencies. The objective of this study was to assess if vaccination against rotavirus, the most common cause of severe diarrhea among children, either as an addition to routine immunization program (RI) or supplemental immunization activity (SIA) would be cost-effective during a humanitarian emergency to decrease diarrhea morbidity and mortality, using Somalia as a case study. Methods An impact and cost-effectiveness analysis was performed comparing no vaccine; two-dose rotavirus SIA and two-dose of RI for the 424,592 births in the 2012 Somali cohort. The main summary measure was the incremental cost per disability-adjusted life-year (DALY) averted. Univariate sensitivity analysis examined the extent to which the uncertainty in the variables affected estimates. Results If introduced in Somalia, a full-series rotavirus RI and SIA would save 908 and 359 lives, respectively, and save US$63,793 and US$25,246 in direct medical costs, respectively. The cost of a RI strategy would be US$309,458. Because of the high operational costs, a SIA strategy would cost US$715,713. US$5.30 per DALY would be averted for RI and US$37.62 per DALY averted for SIA. Variables that most substantially influenced the cost-effectiveness for both RI and SIA were vaccine program costs, mortality rate, and vaccine effectiveness against death. Conclusions Based on our model, rotavirus vaccination appears to be a cost-effective intervention as either RI or SIA, as defined by the World Health Organization as one to three times the per capita Gross Domestic Product (Somalia $112 in 2011). RI would have greater health impact and is more cost effective than SIA, assuming feasibility of reaching the target population. However, given the lack of infrastructure, whether RI is realistic in this setting remains unanswered, and alternative approaches like SIA should be further examined.